$0.00
(Market cap
$69 Mln
Recently Viewed
Clear AllMarket cap
$69 Mln
Revenue (TTM)
$2,552 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-3,242 Mln
ROE
0 %
ROCE
-7.8 %
Industry P/E
--
EV/EBITDA
-4.5
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
235,143,008
CFO
$3,684.39 Mln
EBITDA
$-3,746.52 Mln
Net Profit
$-10,863.78 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Endo International (ENDP)
| -96.3 | 18.3 | -69.0 | -96.7 | -68.6 | -52.7 | -41.4 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Endo International (ENDP)
| -47.6 | 53.1 | -35.8 | -5.8 | -52.9 | -73.1 | -15.1 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including... XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court Read more
Pres, CEO & Director
Mr. Blaise A. Coleman
Pres, CEO & Director
Mr. Blaise A. Coleman
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Endo International plc (ENDP) is $0.14 (NASDAQ) as of 28-Oct-2022 09:30 EDT. Endo International plc (ENDP) has given a return of -68.59% in the last 3 years.
Since, TTM earnings of Endo International plc (ENDP) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Endo International plc (ENDP) are Rs -- and Rs -- as of 24-Apr-2026.
Endo International plc (ENDP) has a market capitalisation of $ 69 Mln as on 11-Nov-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Endo International plc (ENDP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.